Avai Bio develops artificial intelligence software and biotechnology applications as a development-stage company. The company remains pre-revenue and manages a portfolio of early-stage assets. Its primary AI technology, Avant! AI, uses deep learning and unsupervised learning to generate text and build its knowledge base. Other assets include InstantFAME, a system for rating and auctioning digital works, and a mobile news aggregation app. Avai Bio recently shifted its strategy toward the biotech industry, leading to a corporate name change from Avant Technologies. This strategy centers on joint ventures with Austrianova to commercialize cell encapsulation technology. These ventures, Klothonova and Insulinova, aim to apply this technology to biotech and insulin-related cell therapies. Avai Bio does not have a functioning business model and funds its operations through equity issuances and debt, including convertible notes and loans from directors and affiliates. The company's primary costs involve officer compensation, consulting fees, and general administrative expenses. Avai Bio lacks established customers or go-to-market channels, and management describes its commercialization plans as speculative. Future operations depend on the company's ability to raise further capital to advance its joint ventures and software assets.